Oral tofacitinib: Contemporary appraisal of its role in dermatology

Indian Dermatology Online Journal

关键词: Alopecia areata;    atopic dermatitis;    Jakinib;    Janus kinase inhibitors;    psoriasis;    psoriatic arthritis;    tofacitinib;    vitiligo;   

DOI  :  10.4103/idoj.IDOJ_474_18

来源: DOAJ

【 摘 要 】

Tofacitinib, an oral Janus kinase inhibitor (Jakinib), is an emerging treatment modality whose well-established efficacy in systemic inflammatory diseases is now being actively explored for cutaneous disorders (arising due to the patient's dysimmune responses) that are not responding to and/or sustaining intolerable adverse effects with the classical immunosuppressives and other targeted therapies such as the biologics. The most common dermatoses for which oral as well as topical Jakinibs such as tofacitinib have been evaluated and are being used albeit as an off-label indication include psoriasis, psoriatic arthritis, alopecia areata, vitiligo, and atopic dermatitis. This article provides a succinct review on the current status of oral tofacitinib in dermatology through literature search of PubMed database and stresses on the need for further evidence generation to define the drug's place in the therapeutic arsenal of dysimmune cutaneous disorders.

【 授权许可】

Unknown